It also has been reported that SU11274 (SU), another selective c-Met inhibitor, restrains the growth of colorectal carcinoma, which expresses a high level of c-Met [16], and it has antitumor activity in preclinical models of lung, breast, and liver cancer [17,18,19]. Here, MET is linked to colorectal carcinoma.